Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Untreated AML except patients with inv (16), t(8;21), or t (15;17) cytogenetics or AML in first relapse.~2. Patients must have \>/= 2,000 circulating blasts/ul peripheral blood or \>/= 50% blasts in bone marrow biopsy~3. Performance Status 0-2~Exclusion Criteria:~1. Medical, social or psychological factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure.~2. Concurrent or expected need for therapy with corticosteroids during the vaccination phase of the study.~3. History of systemic autoimmune disease~4. Positive antibody to human immunodeficiency virus~5. Patients with Acute promyelocytic Leukemia are not eligible for this study.~6. Good-risk cytogenetics which are: (inv (16), t(8;21), or t (15;17)~7. Positive Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous Dendritic Cells (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).